1. Germany Stocks

  2. •

    Finance

  3. •

    Financial conglomerates
MPH Health Care AG

MPH Health Care AG

24.10
CHF
+0.96
(+4.15%)
98.30MMarket Cap
Apr 29Next Earn
MPH Health Care AG
BX:93M1
(BX Swiss)

Recent

price

24.10

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
EUR
29.54
35.35
52.31
58.77
53.12
61.4
0.01
1.72
1.94
1.28
-2.12
0.83
1.54
1.46
1.43
0.83
- -
Revenue per Share
2.4
2.1
3.74
1.67
1.2
19.29
18.7
7.44
8.65
2.59
-16.44
-2.09
6.8
6.9
7.48
-6.85
- -
Basic EPS, GAAP
0.46
0.16
1.38
-1.96
-2.52
-6.18
-1.59
0.23
1.21
-0.33
-0.68
-0.25
- -
-0.47
0.43
0.03
- -
Free Cash Flow per Basic Share
1.2
1.71
1.64
2.54
1.72
1.92
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
25.06
25.91
24.45
27.81
10.59
32.47
49.97
56.21
62.27
62.85
47.01
44.92
51.72
58.62
64.9
56.85
58.02
Book Value per Share
4.93
5.61
3.15
3.26
2.34
32.47
49.97
56.21
62.27
62.85
47.01
44.92
51.72
58.62
64.9
56.85
58.02
Tangible Book Value per Share
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
Basic Weighted Avg Shares
112
146
206
227
219
263
- -
7
8
5
-9
4
7
6
6
4
- -
Sales/Revenue/Turnover
9.25
7.31
10.63
5.51
4.98
5.27
16,791.49
84.5
459.52
202.96
778.35
-266.54
444.73
483.51
539.27
-800.58
- -
Operating Margin (%)
- -
- -
1
2
2
11
6
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
9
9
15
6
5
83
80
32
37
11
-70
-9
29
30
32
-29
- -
Net Income, GAAP
9.7
12.63
10.09
33.58
9.23
3.67
1.34
0.82
0.85
- -
- -
- -
1.22
0.75
0.88
- -
- -
Effective Tax Rate (%)
8.12
5.94
7.15
2.84
2.26
31.42
170,353.19
431.64
445.17
201.86
776.11
-251.5
440.77
472.88
524.28
-823.85
- -
Profit Margin (%)
13
13
32
28
40
- -
10
8
1
-13
- -
- -
-10
2
-3
-7
-12
Working Capital
4
6
13
17
23
10
14
14
14
3
3
- -
- -
8
5
3
- -
LT Debt
48
49
67
79
95
139
214
241
269
272
201
192
221
251
278
243
248
Total Equity
19.45
15.43
23.31
7.81
8.13
9
4.13
13.28
13.9
- -
- -
- -
13.98
12.35
11.83
- -
- -
Return on Invested Capital (%)
19.46
15.54
14.83
6.17
2.54
59.12
42.88
13.41
13.96
- -
- -
- -
14.02
12.41
11.95
- -
- -
Return on Capital (%)
20.11
17.83
28.45
11.14
7.6
79.49
45.37
14.01
14.53
4.1
-29.76
-4.55
14.07
12.51
12.12
-11.25
- -
Return on Common Equity (%)

Capital Structure

EUR

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
- -
8
- -
LT Borrowings
5
3
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4
4
4
Market Capitalization
- -
- -
107

Working Capital

EUR

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
3
1
3
Cash, Cash Equivalents & STI
3
1
3
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
7
9
16
Payables & Accruals
- -
- -
- -
ST Debt
- -
8
- -
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.56%
4.47%
-12.4%
Free Cash Flow
10,979.83%
21,918.12%
-93.26%
Net Income, GAAP
-154.65%
-138.79%
-191.53%
Sales/Revenue/Turnover
1,511.24%
-20.62%
-41.75%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
6
2025
- -
- -
4
2026
- -
- -
- -

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
7.48
2025
- -
- -
-6.85
2026
- -
- -
- -

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Similar Companies
Strategy Inc (NASDAQ:MSTR)
BitMine Immersion Technologies, Inc. (NYSE:BMNR)
Strive, Inc. (NASDAQ:ASST)
Hyperliquid Strategies Inc (NASDAQ:PURR)
Stablecoin Development Corporation (AMEX:SDEV)
Jio Financial Services Limited (NSE:JIOFIN)
Business
MPH Health Care AG is a Germany-based investment company focused on strategic investments in growth segments of the healthcare market, particularly in chronic diseases, medical aesthetics, and digitalization of healthcare. Its core operations span three main segments: Beauty, Pharma, and Real Estate. The company offers a comprehensive range of products and services including medical-aesthetic beauty treatments and operations; management and provision of medical infrastructure for partner companies; development, manufacture, and sale of pharmaceuticals and medical products targeting therapeutic areas such as oncology, HIV/AIDS, neurology, rheumatology, and other chronic diseases; and medical devices for aesthetic surgery and specialist medical centers. MPH Health Care also provides cytostatic solutions and engages in real estate activities related to its core sectors. The company's portfolio comprises key subsidiaries such as HAEMATO AG, a pharmaceutical firm focused on generics and parallel imports in oncology, HIV, and chronic disease therapies, and M1 Kliniken AG, which specializes in medicinal beauty, offering pharmaceutical and medical products and services along with medical devices for aesthetic surgery and cosmetic dermatology. Founded in 2008 and headquartered in Berlin, Germany, MPH Health Care AG was formerly known as MPH Mittelständische Pharma Holding AG, with the rebranding occurring in 2017. Recent major developments include MPH Health Care AG's continued focus on long-term investment and growth in its healthcare holdings, with a strong emphasis on expanding in high-growth, profitable areas of the medical aesthetic and chronic disease segments. In 2024 and early 2025, the company announced mixed financial results with net asset value fluctuations influenced by investment valuations. Notably, the subsidiary M1 Kliniken AG reported increased consolidated sales by 9.5% and a 29% rise in EBIT in the first quarter of 2025, projecting continued profitable growth with targeted revenue increases in the Beauty segment through 2029. MPH Health Care maintains an attractive dividend policy, proposing a dividend payout of EUR 1.20 per share in 2025. The company also recently navigated challenges involving the insolvency proceedings of an investment, CR Energy AG, without impacting ongoing projects. These strategic, operational, and financial updates underscore MPH Health Care AG's approach to leveraging investments in healthcare innovation and aesthetics in Germany and core European markets.